N/A N=56 Compassion Training and Pain
Chronic Pain
Primary: Change in Brief Pain Inventory — -1.46 units on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 2 N=51 Promoting Tolerance to Common Allergens in High-Risk Children: Global Prevention of Asthma in Children (GPAC) Study
Asthma · Allergic Sensitization
Primary: Number of Participants With Allergic Sensitization at Month 36 Status Post Treatment Completion — 22; 19 participants — p=0.28
Phase 2 N=40 Therapy for Pediatric Relapsed or Refractory Acute Lymphoblastic Leukemia
Acute Lymphoblastic Leukemia · Lymphoma, Lymphoblastic
Primary: Response Rate — 0.846; 0.786; 0.154; 0.214 proportion of participants
N/A N=40 Family-Based Prevention Program for Childhood Anxiety
Anxiety Disorders
Primary: Number of Children With Child Anxiety Diagnosis — 20; 20 participants
Phase 2 N=25 PPX, Temozolomide, and Concurrent Radiation for Newly Diagnosed Brain Tumors
Brain Tumor
Primary: Number of Patients Assessed for Toxicity According to CTC Version 3.0 — 25 participants
N/A N=22 Evaluation of the Candela 1064nm:Nd:YAG Laser for Skin Tightening
Localized Lipodystrophy
Primary: Number of Participants With Mild to Moderate Reduction in Cellulite. — 3; 2 participants
Phase 4 N=54 Comparison of Diltiazem and Metoprolol in the Management of Acute Atrial Fibrillation or Atrial Flutter
Heart Rate and Rhythm Disorders
Primary: Percent of Patients Reaching Target HR<100bpm Within 30 Minutes — 46.4; 95.8 percentage of participants — p=.0001
N/A N=132 Genotypic and Phenotypic Correlates of Resistance to Aspirin
Platelet Dysfunction Due to Aspirin
Primary: Whole Blood Coagulation — 453.8 Aspirin response units (ARU)
Phase 2 N=97 Ofatumumab Plus Bendamustine in Frontline and Relapsed Chronic Lymphocytic Leukaemia (CLL)
Chronic Lymphocytic Leukemia (CLL) · Leukaemia, Lymphocytic, Chronic
Primary: Number of Participants With Overall Response (OR), as Assessed by the Investigator — 19; 6; 2; 2 Participants
N/A N=192 AMPLATZER Duct Occluder II Clinical Study
Patent Ductus Arteriosus
Primary: The Primary Safety Endpoint is the Rate of Device and Procedure Related Serious Adverse Events (SAE) 180 Days Post Procedure. — 1.6 percentage of participants
N/A N=102 Relationship Between Bladder Distention and Hysteroscopy Application
Menorrhagia
Primary: Ease of Cervical Entry — 4.00; 3.55 units on a scale
N/A N=77 Preoperative Etanercept Before Inguinal Hernia Surgery
Inguinal Hernia · Postoperative Pain
Primary: Numerical Rating Scale Pain Score — 3.3; 3.9 units on a scale
Phase 4 N=112 Patient Preference Comparison of AZARGA Versus COSOPT
Open-Angle Glaucoma · Ocular Hypertension
Primary: Preferred Treatment — 60.2; 39.8 Percentage of participants
Phase 3 N=2,278 RED-HF™ Trial - Reduction of Events With Darbepoetin Alfa in Heart Failure Trial
Heart Failure · Anemia · Cardiovascular Disease
Primary: Time to All Cause Death or First Hospitalization for Worsening Heart Failure — 1260.0; 1184.0 days — p=0.871
Phase 2 N=67 A Randomized Phase 2 Pharmacokinetic Trial of Chemotherapy With or Without Panitumumab in Patients With Metastatic and/or Recurrent Squamous Cell Carcinoma of the Head and Neck
Squamous Cell Carcinoma of Head and Neck
Primary: Area Under the Curve (AUC) of Total Plasma Cisplatin-derived Platinum Levels With and Without the Presence of Panitumumab — 58000; 62300 ng*hr/mL